(Reuters) - U.S. health regulators expanded the approval of Roche Holding AG's breast cancer drug Perjeta and will now allow its use to help shrink tumors prior to surgery, the Food and Drug Administration said on Monday.
via Reuters: Health News Read More Here..
No comments:
Post a Comment